Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abbv-927 + nab-paclitaxel + abbv-368
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**ABBV-927 + nab-paclitaxel + ABBV-368** is an investigational combination regimen for cancer therapy, specifically explored in early-phase trials for advanced and metastatic solid tumors such as non-small cell lung cancer and triple-negative breast cancer. - **ABBV-927** is a monoclonal antibody agonist targeting CD40, a costimulatory molecule critical for both innate and adaptive immune system activation, essential in T-cell activation and proliferation. - **ABBV-368** is a monoclonal antibody agonist of OX40, another costimulatory molecule that enhances immune response and suppresses regulatory T-cell activity. - **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic microtubule inhibitor used routinely to treat various cancers. This triplet aims to provide both immune activation (via CD40 and OX40 agonism) and cytotoxic action (via paclitaxel) to improve antitumor outcomes. The combination is being evaluated by AbbVie in Phase 1 clinical studies for solid tumors[1][5][7].
- Brand names
- None found specific to this unique triplet combination
- Other names
- None found specific to this unique triplet combination
02
Targets
CD40 (Cluster of differentiation 40 receptor)CD28 (Cluster of Differentiation 28)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on abbv-927 + nab-paclitaxel + abbv-368.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abbv-927 + nab-paclitaxel + abbv-368.